CIK 0001802665
- Large accelerated filer
Harmony Biosciences Holdings, Inc.
Sign in to watch- Ticker
- HRMY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 822279923
- Phone
- +1 484-539-9800
- Business address
- 630 W GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING, PA, 19462
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,108,586
- in 2 filings
Net −$3,108,586. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-08-21 | Serafin Andrew Chief Business Officer | Conversion · Series C Preferred Stock | −51,021 | 0 | ||
| 2020-08-21 | Valor IV Pharma Holdings, LLC 10% owner | Conversion | +10,139,645 | 10,984,981 | ||
| 2020-08-21 | Valor IV Pharma Holdings, LLC 10% owner | Conversion | +233,052 | 11,218,033 | ||
| 2020-08-21 | Valor IV Pharma Holdings, LLC 10% owner | Conversion · Series A Preferred Stock | −75,000,000 | 0 | ||
| 2020-08-21 | Valor IV Pharma Holdings, LLC 10% owner | Conversion · Series C Preferred Stock | −1,786,985 | 0 | ||
| 2020-08-21 | Novo Holdings A/S 10% owner | Conversion | +4,277,300 | 4,277,300 | ||
| 2020-08-21 | Novo Holdings A/S 10% owner | Purchase | +132,503 | $24.00 | $3.2M | 4,409,803 |
| 2020-08-21 | Novo Holdings A/S 10% owner | Conversion · Series A Convertible Preferred Stock | −25,000,000 | 0 | ||
| 2020-08-21 | Novo Holdings A/S 10% owner | Conversion · Series C Convertible Preferred Stock | −1,860,107 | 0 | ||
| 2020-08-21 | Marshman Fund Trust II 10% owner | Conversion | +4,026,784 | 10,958,547 | ||
| 2020-08-21 | Marshman Fund Trust II 10% owner | Conversion · Series A Preferred Stock | −25,983,571 | 0 | ||
| 2020-08-21 | Serafin Andrew Chief Business Officer | Conversion | +32,214 | 32,214 | ||
| 2020-08-21 | Serafin Andrew Chief Business Officer | Conversion | +6,871 | 39,085 | ||
| 2020-08-21 | Serafin Andrew Chief Business Officer | Conversion · Series A Preferred Stock | −207,869 | 0 | ||
| 2020-08-21 | Serafin Andrew Chief Business Officer | Conversion · Series C Preferred Stock | −51,681 | 0 | ||
| 2020-08-21 | Valor IV Pharma Holdings, LLC 10% owner | Conversion | +12,080,352 | 12,925,688 | ||
| 2020-08-21 | Valor IV Pharma Holdings, LLC 10% owner | Conversion | +240,668 | 13,166,357 | ||
| 2020-08-21 | Valor IV Pharma Holdings, LLC 10% owner | Conversion · Series A Preferred Stock | −77,950,712 | 0 | ||
| 2020-08-21 | Valor IV Pharma Holdings, LLC 10% owner | Conversion · Series C Preferred Stock | −1,810,126 | 0 | ||
| 2020-08-21 | Nielsen Jack Director | Purchase | +24,812 | $24.00 | $595K | 27,548 |
Page 25 of 26 · 511 trades